by Plus Therapeutics | May 14, 2025 | LM
New Data on REYOBIQ™ for Leptomeningeal Metastases Presented at the NMN Conference! Plus Therapeutics is pleased to announce that new clinical data on its lead investigational therapy, REYOBIQ™ (rhenium Re 186 obisbemeda), was presented at the Nuclear Medicine and...
by Plus Therapeutics | May 1, 2025 | GBM, LM, PBC, Uncategorized
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
by Plus Therapeutics | Apr 22, 2025 | GBM
REYOBIQ™ Clinical Trial for Recurrent Glioma Featured in Oncolytics Today We’re proud to share that Plus Therapeutics’ innovative work on REYOBIQ™ (rhenium-186 Re obisbemeda) has been featured as the cover story in the latest issue of Oncolytics Today, published by...
by Plus Therapeutics | Apr 15, 2025 | LM
Plus Therapeutics to Present New REYOBIQ™ Clinical Data at Nuclear Medicine Symposium 2025 We’re excited to announce that Plus Therapeutics will present new data on our lead radiotherapeutic compound, REYOBIQ™ (rhenium Re186 obisbemeda), at the upcoming Nuclear...
by Plus Therapeutics | Apr 12, 2025 | GBM, LM, PBC, Uncategorized
Advancing Radiotherapeutic Solutions for Rare Cancers At Plus Therapeutics, our mission is clear: to develop safe, effective, and lasting solutions for patients facing rare and hard-to-treat cancers. Every day, our dedicated team works alongside clinicians and...
Recent Comments